|                          | All          | EPA (N =10)  | Control (N = 9) | P   |
|---------------------------|--------------|--------------|-----------------|-----|
| Age (years)               | 58.7 ± 14.3  | 60.8 ± 17.0  | 56.3 ± 11.1     | 0.446 |
| Diabetic duration (years) | 11.5 ± 7.5   | 14.5 ± 8.1   | 8.2 ± 5.6       | 0.107 |
| Sex (Male/Femal)          | 17/2         | 8/2          | 9/0             |     |
| OHA (None/BG/DPP4i/Gli/Gl/Pio/SGLT2i) | 1/10/4/1/1/1/2 | 1/8/0/1/0/1/1 | 0/2/4/0/1/0/1 |     |
| Rapid-acting insulin/Long-acting insulin / GLP-1 RA | 2/3/2 | 1/2/2 | 1/1/0 |     |
| HT (None/ARB/CCB/Diuretic/β blocker/α blocker) | 10/9/6/1/1/1 | 7/3/2/0/0/0 | 3/6/4/1/0/1 |     |
| DL (None/Statin/Fibrate/Ezetimib/Colestimide) | 8/10/1/1/1 | 4/6/0/0/1 | 4/4/1/0/1 |     |
| Selenoprotein P (mg/L)    | 4.39 ± 0.64  | 4.30 ± 0.76  | 4.49 ± 0.50     | 0.537 |
| Selenium (μg/L)           | 138.0 ± 20.7 | 138.5 ± 26.9 | 137.3 ± 12.4    | 0.904 |
| Eicosapentaenoic acid (μg/mL) | 85.3 ± 54.3 | 73.7 ± 25.3 | 98.2 ± 74.6     | 0.372 |
| Fasting plasma glucose (mg/dL) | 126.6 ± 22.1 | 126.9 ± 20.4 | 126.2 ± 25.1   | 0.889 |
| Hemoglobin A1c (%)        | 7.2 ± 1.4    | 7.6 ± 1.7    | 6.6 ± 0.8       | 0.218 |
| C-peptide immunoreactivity (ng/mL) | 2.3 ± 1.0 | 2.2 ± 0.6 | 2.4 ± 1.3 | 0.780 |
| Body weight (kg)          | 75.8 ± 19.4  | 72.8 ± 15.4  | 79.1 ± 23.7     | 0.968 |
| Body mass index (kg/m²)   | 26.4 ± 5.3   | 25.3 ± 3.9   | 27.7 ± 6.5      | 0.497 |
| Waist circumference (cm)  | 94.5 ± 15.7  | 91.9 ± 11.5  | 97.3 ± 19.7     | 0.952 |

All values are means ± standard deviation. P-value for the intergroup comparison (baseline). OHA, oral hypoglycemic agent; BG, biguanide; SU, sulphonylurea; DPP4i, dipeptidyl peptidase-4 inhibitor; Gli, glinide; Gl, alpha-glucosidase inhibitor; Pio, pioglitazone; SGLT2i, sodium-glucose linked transporter type 2 inhibitor; GLP1RA, glucagon-like peptide 1 receptor agonist; HT, hypertension; ARB, angiotensin II receptor antagonist; CCB, calcium channel blocker; DL, dyslipidemia; EPA, eicosapentaenoic acid